Drugmaker Cheplapharm weighs $10B IPO

Cheplapharm Arzneimittel GmbH, the German drugmaker, is weighing plans for an initial public offering in what could be one of Europe’s largest share sales of 2021, people familiar with the matter said. Cheplapharm is speaking with advisers about a listing as soon as this year. A share sale could value the business at about 7 billion to 8 billion euros ($9.5 billion) or more. A Cheplapharm representative declined comment.